SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Crowe DL, Tsang KJ, Shemirani B. Jun N-terminal kinase 1 mediates transcriptional induction of matrix metalloproteinase 9 expression. Neoplasia 2001; 3: 2732.
  • 2
    Martinella-Catusse C, Polette M, Noel A, Giles C, Dehan F, Munaut C. 2001. Down-regulation of MT1-MMP expression by the alpha 3 chain of type IV collagen inhibits bronchial tumor cell line invasion. Lab Invest 2001; 81: 16775.
  • 3
    Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001; 13: 11723.
  • 4
    Jurasz P, Sawicki G, Dussyk M, Sawicka J, Miranda C, Mayers I, Radomski MW. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide. Cancer Res 2001; 61: 37682.
  • 5
    Bor-Ching S, Su-Ming H, Hong-Nerng H, Huang-Chun L, Su-Cheng H, Rong-Hwa L. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61: 23742.
  • 6
    Dove A. MMP inhibitors: Glimmers of hope amidst clinical failures. Nat Med 2002; 8: 95.
  • 7
    Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev/Cancer 2002; 2: 16174.
  • 8
    Pritchard SC, Nicolson MC, Lloret C, McKay JA, Ross VG, Kerr KM, Murray, GI, McLeod HL. Expression of matrix metalloproteinases 1, 2, 9 and their tissue inhibitors in stage II non-small cell lung cancer: implications for MMP inhibition therapy. Oncol Rep 2001; 8: 4214.
  • 9
    Yamamoto H, Itoh F, Iku S, Adachi Y, Fukushima H, Sasaki S, Mukaiya M, Hirata K, Imai K. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human pancreatic adenocarcinomas: clinicopathologic and prognostic significance of matrilysin expression. J Clin Oncol 2001; 19: 111827.
  • 10
    Skiles JW, Gonnella NC, Jeng AY. The design, structure and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 2001; 8: 4257.
  • 11
    Airola K, Fusenig NE. Differential stromal regulation of MMP-1 expression in benign and malignant keratinocytes. J Invest Dermatol 2001; 116: 8592.
  • 12
    Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI, Strongin AY. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001; 356: 70518.
  • 13
    Kermorgant S, Aparicio T, Dessirier V, Lewin MJ, Lehy T. Hepatocyte growth factor induces colonic cancer cell invasiveness via enhanced motility and protease overproduction. Evidence for PI3 kinase and PKC involvement. Carcinogenesis 2001; 22: 103542.
  • 14
    Wollina U, Hipler UC, Knoll B, Graefe T, Kaatz M, Kirsch K. Serum matrix metalloproteinase-2 in patients with malignant melanoma. J Cancer Res Clin Oncol 2001; 127: 6315.
  • 15
    Ylisirnio S, Hoyhtya M, Makitaro R, Paaakko P, Risteli J, Kinnula VL, Turpeanniemi-Hujanen T, Jukkola A. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitors of metalloproteinase (TIMP-1) are associated with poor prognosis in lung cancer. Clin Cancer Res 2001; 7: 16337.
  • 16
    Sheen-Chen S, Chen H, Eng H, Sheen C, Chen W. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001; 173: 7982.
  • 17
    Moses MA, Wiederschain D, Loughlin KR, Zurakowski D, Lamb CC, Freeman MR. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 1998; 58: 13959.
  • 18
    Durkan GC, Nutt JE, Rajjayabun PH, Neal DE, Lunec J, Killian Mellon J. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. Clin Cancer Res 2001; 7: 34506.
  • 19
    Farias EF, Ranuncolo SM, Cresta C, Specterman S, Armanasco E, Varela M, Lastiri MJ, Pallotta MG, Bal de Kier Joffé ED, Puricelli LI. Plasma metalloproteinase activity is enhanced in the euglobulin fraction of breast and lung cancer patients. Int J Cancer (Pred Oncol) 2000; 89: 38994.
  • 20
    Ranuncolo SM, Matos E, Loria D, Vilensky M, Rojo R, Bal de Kier Joffé ED, Puricelli LI. Circulating 92-Kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck.
  • 21
    FletcherRH, FletcherSW, WagnerEH, eds. Clinical epidemiology. The essentials. 2nd ed. Baltimore: Williams and Wilkins, 1988. 4275.
  • 22
    Boyd NF. The epidemiology of breast cancer. In: SouhamiRL, TannockI, HohenbergerP, HoriotJC. Oxford textbook of oncology. 2nd ed. vol. 1. New York: Oxford University Press, 2002. 172534.
  • 23
    Duffy MJ. Biochemical markers in breast cancer: which ones are clinically useful? Clin Biochem 2001; 34: 34752.
  • 24
    Perou C, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 74752.
  • 25
    Lumachi F, Brandes AA, Boccagni P, Polistina F, Favia G, D'Amico DF. Long-term follow-up study in breast cancer patients using serum tumor markers CEA and CA 15-3. Anticancer Res 1999; 19: 448590.
  • 26
    Lauro S, Trasatti L, Bordin F, Lanzetta G, Bria E, Gelibter A, Reale, MG, Vecchione A. Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients. Anticancer Res 1999; 19: 35116.
  • 27
    Molina R, JO J, Filella X, Zanón G, Farrus B, Muñoz M, Latre ML, Pahisa J, Velasco M, Fernandez P, Estapé J, Ballesta AM. C-erb-2 CEA and CA 15.3 serum levels in the early diagnosis of recurrence in breast cancer patients. Anticancer Res 1999; 19: 25516.
  • 28
    Canizares F, Sola J, Perez M, Tovar I, De Las Heras M, Salinas J, Penafiel R, Martinez P. Preoperative values of CA 15-3 and CEA as prognostic factors in breast cancer: a multivariate analysis. Tumor Biol 2001; 22: 27381.
  • 29
    Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: a prognostic marker in breast cancer. Int J Biol 2000; 15: 3303.
  • 30
    Zucker S, Hymowitz M, Conner C, Zarrabi HM, Hurewitz AN, Matrisian L, Boyd D, Nicolson G, Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Ann NY Acad Sci 1999; 878: 21227.
  • 31
    Fernö M. Prognostic factors in breast cancer: A brief review. Anticancer Res 1998; 18: 216772.
  • 32
    Mittra I. Prognostic factors and staging. In: SouhamiRL, TannockI, HohenbergerP, HoriotJC, eds. Oxford textbook of oncology. 2nd ed. vol. 1. New York: Oxford University Press, 2002. 172534.
  • 33
    Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Cannolly JL, Hayes DF, Edge SB, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 96678.
  • 34
    Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Taleuchi H, Shirasuna, K. Expression of MMPs, MT-MMP and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999; 21: 62738.
  • 35
    Hashimoto N, Ikobayashi M, Tsuji T. 1998. Serum Type IV collagen-degrading enzyme in hepatocellular carcinoma with metastasis. Acta Med Okayama 1998;42: 16.
  • 36
    McCarthy K, Maguirre T, McGreal G, McDermott E, O'Higgins N, Duffy MJ. High levels of tissue inhibitors of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int J Cancer (Pred Oncol) 1999;84: 448.
  • 37
    Remacle A, McCarthy K, Noël A, Maguirre T, McDermott E, O'Higgins N, Foidart JM, Duffy MJ. High levels of TIMP-2 correlate with adverse prognosis in breast cancer. Int J Cancer (Pred Oncol) 2000;89: 11821.
  • 38
    Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, Brünner N, Jänicke F, Meijer-van Gelder ME, Henzen-Logmans SC, van Putten WLJ, Klijn JGM. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res 2000;60: 63643.